$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000162828022003661 Filed on February 24, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$156.2M	$45.23M	$124.2M
YoY Change	25.77%	14.82%	5.37%
Cost Of Revenue	$50.16M	$11.58M	$39.95M
YoY Change	25.55%	9.35%	6.33%
Gross Profit	$106.0M	$33.65M	$84.23M
YoY Change	25.88%	16.81%	4.92%
Gross Profit Margin	67.88%	74.39%	67.83%
Selling, General & Admin	$97.59M	$18.24M	$68.84M
YoY Change	41.77%	11.36%	12.59%
% of Gross Profit	92.05%	54.21%	81.73%
Research & Development	$16.29M	$3.120M	$13.02M
YoY Change	25.09%	-3.11%	-57.16%
% of Gross Profit	15.36%	9.27%	15.46%
Depreciation & Amortization	$3.000M	$730.0K	$2.400M
YoY Change	25.0%	28.07%	41.18%
% of Gross Profit	2.83%	2.17%	2.85%
Operating Expenses	$113.9M	$21.36M	$81.86M
YoY Change	39.12%	9.04%	-10.57%
Operating Profit	-$7.854M	$12.29M	$2.372M
YoY Change	-431.11%	33.43%	-121.08%
Interest Expense	$4.000K	$120.0K	$6.000K
YoY Change	-33.33%	-62.5%	-25.0%
% of Operating Profit		0.98%	0.25%
Other Income/Expense, Net	$272.0K	-$10.00K	$672.0K
YoY Change	-59.52%	-66.67%	-57.63%
Pretax Income	-$7.582M	$12.40M	$3.044M
YoY Change	-349.08%	30.53%	-131.5%
Income Tax	-$111.0K	$180.0K	$180.0K
% Of Pretax Income		1.45%	5.91%
Net Earnings	-$7.471M	$12.22M	$2.864M
YoY Change	-360.86%	28.62%	-129.63%
Net Earnings / Revenue	-4.78%	27.02%	2.31%
Basic Earnings Per Share	-$0.16	$0.27	$0.06
Diluted Earnings Per Share	-$0.16	$0.25	$0.06
COMMON SHARES
Basic Shares Outstanding	46.47M shares	45.43M shares	45.22M shares
Diluted Shares Outstanding	46.47M shares		47.28M shares

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$103.4M	$75.80M	$75.80M
YoY Change	36.41%	8.75%	8.75%
Cash & Equivalents	$68.33M	$33.62M	$33.60M
Short-Term Investments	$35.07M	$42.20M	$42.20M
Other Short-Term Assets	$4.246M	$3.893M	$3.900M
YoY Change	8.87%	31.83%	30.0%
Inventory	$13.38M	$9.356M	$9.400M
Prepaid Expenses
Receivables	$37.44M	$34.50M	$34.50M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$158.5M	$123.6M	$123.6M
YoY Change	28.21%	10.66%	10.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$59.03M	$57.70M	$57.70M
YoY Change	2.3%	79.19%	79.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$25.69M	$24.10M	$24.10M
YoY Change	6.59%	161.96%	161.96%
Other Assets	$528.0K	$0.00	$200.0K
YoY Change	164.0%	-100.0%	100.0%
Total Long-Term Assets	$85.24M	$82.05M	$82.00M
YoY Change	3.95%	97.31%	97.59%
TOTAL ASSETS
Total Short-Term Assets	$158.5M	$123.6M	$123.6M
Total Long-Term Assets	$85.24M	$82.05M	$82.00M
Total Assets	$243.7M	$205.6M	$205.6M
YoY Change	18.53%	34.18%	34.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.016M	$6.755M	$6.800M
YoY Change	32.59%	6.46%	7.94%
Accrued Expenses	$17.00M	$11.29M	$15.70M
YoY Change	8.25%	42.09%	17.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$41.00K	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$26.05M	$22.48M	$22.50M
YoY Change	15.79%	13.58%	13.64%
LONG-TERM LIABILITIES
Long-Term Debt	$44.00K	$100.0K	$100.0K
YoY Change	-56.0%	0.0%	0.0%
Other Long-Term Liabilities	$47.15M	$76.00K	$48.80M
YoY Change	-3.39%	-30.91%	119.82%
Total Long-Term Liabilities	$47.19M	$76.00K	$48.90M
YoY Change	-3.49%	-30.91%	119.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.05M	$22.48M	$22.50M
Total Long-Term Liabilities	$47.19M	$76.00K	$48.90M
Total Liabilities	$73.24M	$71.35M	$71.30M
YoY Change	2.73%	69.28%	69.36%
SHAREHOLDERS EQUITY
Retained Earnings		-$375.8M
YoY Change		-0.76%
Common Stock		$510.1M
YoY Change		4.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$170.5M	$134.3M	$134.3M
YoY Change
Total Liabilities & Shareholders Equity	$243.7M	$205.6M	$205.6M
YoY Change	18.53%	34.18%	34.2%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$7.471M	$12.22M	$2.864M
YoY Change	-360.86%	28.62%	-129.63%
Depreciation, Depletion And Amortization	$3.000M	$730.0K	$2.400M
YoY Change	25.0%	28.07%	41.18%
Cash From Operating Activities	$29.04M	$11.33M	$17.57M
YoY Change	65.26%	259.68%	-344.63%
INVESTING ACTIVITIES
Capital Expenditures	$7.915M	-$1.070M	$2.626M
YoY Change	201.41%	197.22%	0.38%
Acquisitions
YoY Change
Other Investing Activities	$4.414M	-$24.60M	-$14.53M
YoY Change	-130.38%	72.75%	-209.83%
Cash From Investing Activities	-$3.501M	-$25.68M	-$17.16M
YoY Change	-79.6%	75.89%	-261.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$9.171M	4.450M	$6.441M
YoY Change	42.38%	190.85%	22.45%
NET CHANGE
Cash From Operating Activities	$29.04M	11.33M	$17.57M
Cash From Investing Activities	-$3.501M	-25.68M	-$17.16M
Cash From Financing Activities	$9.171M	4.450M	$6.441M
Net Change In Cash	$34.71M	-9.900M	$6.853M
YoY Change	406.49%	-0.2%	-21.16%
FREE CASH FLOW
Cash From Operating Activities	$29.04M	$11.33M	$17.57M
Capital Expenditures	$7.915M	-$1.070M	$2.626M
Free Cash Flow	$21.13M	$12.40M	$14.95M
YoY Change	41.34%	253.28%	-252.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2019	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2019	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021	us-gaap	Defined Contribution Plan Tax Status Extensible List DefinedContributionPlanTaxStatusExtensibleList	http://fasb.org/us-gaap/2021-01-31#QualifiedPlanMember
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-35280
CY2021	dei	Entity Registrant Name EntityRegistrantName	VERICEL CORPORATION
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MI
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3096597
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	64 Sidney Street
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2021	dei	City Area Code CityAreaCode	617
CY2021	dei	Local Phone Number LocalPhoneNumber	588-5555
CY2021	dei	Security12b Title Security12bTitle	Common Stock (No par value)
CY2021	dei	Trading Symbol TradingSymbol	VCEL
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	2430875370	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	46967681	shares
CY2021	dei	Auditor Firm AuditorFirmId	238
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68330000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33620000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	35068000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50105000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	42187000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	40000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	143000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	37437000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34504000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	13381000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	9356000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4246000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3893000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	158462000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	123560000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	13308000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7633000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	211000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	211000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45720000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	25687000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	24099000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	317000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2021Q4	us-gaap	Assets Assets	243705000	USD
CY2020Q4	us-gaap	Assets Assets	205608000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9016000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6755000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14045000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11293000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2950000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4394000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	41000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	41000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26052000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22483000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47147000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48789000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	44000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	76000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	73243000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	71348000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46880000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46880000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45804000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45804000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	553902000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	510061000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-154000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-383286000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375815000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	170462000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	134260000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	243705000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	205608000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	153075000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	121968000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	117850000	USD
CY2021	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	3109000	USD
CY2020	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	2211000	USD
CY2019	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	0	USD
CY2021	us-gaap	Revenues Revenues	156184000	USD
CY2020	us-gaap	Revenues Revenues	124179000	USD
CY2019	us-gaap	Revenues Revenues	117850000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	50159000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	39951000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	37571000	USD
CY2021	us-gaap	Gross Profit GrossProfit	106025000	USD
CY2020	us-gaap	Gross Profit GrossProfit	84228000	USD
CY2019	us-gaap	Gross Profit GrossProfit	80279000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16287000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13020000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30391000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	97592000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	68836000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61139000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	113879000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	81856000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	91530000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-7854000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	2372000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-11251000	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	224000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	691000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	1614000	USD
CY2021	us-gaap	Interest Expense InterestExpense	4000	USD
CY2020	us-gaap	Interest Expense InterestExpense	6000	USD
CY2019	us-gaap	Interest Expense InterestExpense	8000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	52000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-13000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	272000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	672000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1586000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7582000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3044000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9665000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-111000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	180000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7471000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	2864000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9665000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46472000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45221000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44180000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46472000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47282000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44180000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7471000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	2864000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9665000	USD
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-168000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-7000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	60000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7639000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2857000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9605000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	102231000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9665000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13179000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4354000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	932000	USD
CY2019	vcel	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	0	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	60000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	111091000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	2864000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13843000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5582000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1050000	USD
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	163000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-7000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	134260000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7471000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34322000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9928000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1256000	USD
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1665000	USD
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-168000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	170462000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7471000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	2864000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9665000	USD
CY2021	us-gaap	Depreciation Depreciation	2965000	USD
CY2020	us-gaap	Depreciation Depreciation	2383000	USD
CY2019	us-gaap	Depreciation Depreciation	1744000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	34322000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	13843000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	13179000	USD
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-949000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-318000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	610000	USD
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4422000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4445000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2787000	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-7000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-93000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-42000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4025000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2540000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3258000	USD
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2933000	USD
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2336000	USD
CY2019	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	8714000	USD
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	353000	USD
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	940000	USD
CY2019	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	106000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1491000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	33000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1024000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2752000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3345000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1018000	USD
CY2021	vcel	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-3086000	USD
CY2020	vcel	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-3951000	USD
CY2019	vcel	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2512000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	15000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-64000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	29040000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	17572000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7183000	USD
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	60021000	USD
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	63057000	USD
CY2019	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	72346000	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	64435000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	48523000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	85577000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7915000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2626000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2616000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3501000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17160000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10615000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11184000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6632000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5286000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1665000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	163000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-348000	USD
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-28000	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-26000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9171000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6441000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5260000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34710000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6853000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8692000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33831000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26978000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18286000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68541000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33831000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26978000	USD
CY2021	vcel	Warrants Exercised For Common Stock WarrantsExercisedForCommonStock	0	USD
CY2020	vcel	Warrants Exercised For Common Stock WarrantsExercisedForCommonStock	0	USD
CY2019	vcel	Warrants Exercised For Common Stock WarrantsExercisedForCommonStock	104000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	192000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	29573000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	2599000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1373000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	531000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	217000	USD
CY2021	vcel	Restricted Stock Held For Employee Tax Remittance Included In Accounts Payable RestrictedStockHeldForEmployeeTaxRemittanceIncludedInAccountsPayable	46000	USD
CY2020	vcel	Restricted Stock Held For Employee Tax Remittance Included In Accounts Payable RestrictedStockHeldForEmployeeTaxRemittanceIncludedInAccountsPayable	0	USD
CY2019	vcel	Restricted Stock Held For Employee Tax Remittance Included In Accounts Payable RestrictedStockHeldForEmployeeTaxRemittanceIncludedInAccountsPayable	0	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	4000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	6000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	8000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	379000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	147000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	80000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68330000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33620000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26889000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	211000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	211000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	89000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68541000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33831000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26978000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Organization<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets two cell therapy products in the U.S., MACI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (autologous cultured chondrocytes on porcine collagen membrane) and Epicel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (cultured epidermal autografts).</span></div><div style="text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) for North American rights to NexoBrid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a registration-stage biological orphan product for debridement of severe thermal burns. The Company operates its business primarily in the U.S. in one reportable segment — the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing pandemic caused by the spread of a novel strain of coronavirus (“COVID-19”) has created significant disruptions to the U.S. and global economy and has contributed to significant volatility in financial markets. The global impact of the outbreak has fluctuated since early 2020. At times, many state, local and national governments – including those in Massachusetts and Michigan, where the Company’s operations are located – have responded by issuing, extending and supplementing orders requiring quarantines, restrictions on travel, and the mandatory closure of certain non-essential businesses, among other actions. In the U.S., the status and application of these orders have varied on a state-by-state basis since the early days of the pandemic. Many of the restrictions have been periodically updated as infection rates in the U.S. have risen and fallen, as new virus variants have emerged, as vaccines have been distributed and administered, and as world health leaders learn more about the virus, its transmission pathway and who is most at risk. Because Vericel is deemed an essential business, the Company has been exempted from government orders requiring the closure of workplaces and the cessation of business operations.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding being an essential business, the Company’s business and operations at times have been adversely impacted by the ongoing effects of the COVID-19 pandemic. For example, as a result of periodic restrictions placed on the performance of elective surgical procedures, Vericel experienced a significant increase in cancellations of scheduled MACI procedures, as well as a slowdown in new MACI orders during March and April of 2020. The widespread suspension of surgical procedures impacted the Company’s business and operations during the first and second quarters of 2020. The level and degree of restriction on elective surgeries, on the ability of patients to seek treatment and on U.S. business operations generally fluctuated throughout 2020 as COVID-19 infection rates rose and fell during the summer months and into the autumn. By the first quarter of 2021, the pandemic’s effects on the Company’s MACI business had largely dissipated. During the summer of 2021, however, the pandemic’s direct and ancillary effects again began to cause some disruption to our MACI business. Following the cessation of COVID-19-related travel restrictions in many parts of the U.S. and the availability of vaccinations in May and June 2021, some MACI patients postponed or delayed treatment – opting instead to take vacation and/or travel. Further, surges of new COVID-19 cases during the second half of 2021 caused by the spread of the “Delta” and “Omicron” variants again caused disruptions to health care networks including restrictions on the performance of elective surgical procedures, the availability of physicians and/or their treatment prioritizations, the level of healthcare facility staffing and, in some instances, the willingness or ability of patients to seek treatment. Consequently, and notwithstanding the widespread distribution of vaccines, these factors contributed to a slowdown of MACI procedures during the third and fourth quarters of 2021. Although hospitals are now better prepared for subsequent surges in COVID-19 patients, the risk remains that regional or local restrictions could again be placed on the performance of elective surgical procedures if the number of COVID-19 infections in the U.S. were to continue to rise, or if new or existing COVID-19 variants render current vaccine treatments ineffective. </span></div><div style="text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because Epicel is used almost exclusively in an emergent setting by burn centers and surgeons throughout the country, Epicel revenue and procedure volumes have been less affected by the pandemic. Nevertheless, large burns and burn admissions can be affected by restrictions on human activity resulting from more severe government lockdown orders. </span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the outset of the pandemic, the Company put in place a comprehensive workplace protection plan, which instituted protective measures in response to COVID-19. Vericel’s workplace protection plan has closely followed guidance issued by the Centers for Disease Control and Prevention (“CDC”) and has complied with applicable federal and state law. To date, Vericel has been successful in sustaining its operations and providing MACI and Epicel to patients in need. The Company continues to review its policies and procedures regularly, including its workplace protection plan, as the pandemic evolves and the Company may take additional actions to the extent required.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of December 31, 2021, the Company had an accumulated deficit of $383.3 million and had a net loss of $7.5 million for the year ended December 31, 2021. The Company had cash and cash equivalents of $68.3 million and investments of $60.8 million as of December 31, 2021. The Company expects that cash from the sales of its products and existing cash, cash equivalents and investments will be sufficient</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to support the Company’s current operations through at least 12 months from the issuance of these consolidated financial statements. The effects of the COVID-19 pandemic continue to evolve, however. To the extent the U.S. experiences a continued worsening in COVID-19 infections or the emergence of additional virus variants that result in more serious disease or limit the effectiveness of existing vaccines, subsequent healthcare measures – to include the postponement or cessation of elective and other surgical procedures – may cause the Company to experience a reduction in business and resulting revenue. This, consequently, may result in irrecoverable losses of customers and significantly impact long-term liquidity, requiring the Company to engage in layoffs, furloughs and/or reductions in salaries. The Company also may need to access additional capital; however, the Company may not be able to obtain financing on acceptable terms or at all, particularly in light of the impact of COVID-19 on the global economy and financial markets. The terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders.</span></div>
CY2021Q4	vcel	Number Of Products NumberOfProducts	2	pharmacy
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-383300000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7500000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68300000	USD
CY2021Q4	us-gaap	Investments Investments	60800000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company is monitoring the potential impact of the ongoing COVID-19 pandemic on its business and the consolidated financial statements. The more significant estimates reflected in the Company’s consolidated financial statements include, but are not limited to, certain judgments regarding revenue recognition, inventory valuation, stock option valuation, deferred tax assets and liabilities and accrued expenses. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments reflected in these consolidated financial statements or a revision of the carrying value of its assets or liabilities as of the issuance of these consolidated financial statements. These estimates may change as new events occur and additional information is obtained. Actual results could materially differ from those estimates.</span></div>
CY2020	us-gaap	Revenues Revenues	124179000	USD
CY2019	us-gaap	Revenues Revenues	117850000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	27630000	USD
CY2021Q4	vcel	Number Of Contracted Specialty Pharmacies NumberOfContractedSpecialtyPharmacies	2	pharmacy
CY2021Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	7000000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Other Receivables Current AllowanceForDoubtfulOtherReceivablesCurrent	5300000	USD
CY2021	vcel	Revenue Revenue Recognized Changein Uncollectible Analysis Percentage RevenueRevenueRecognizedChangeinUncollectibleAnalysisPercentage	0.0050
CY2021	vcel	Revenue Revenue Recognized Effect Of0.5 Change In The Estimated Uncollectible Percentage Amount RevenueRevenueRecognizedEffectOf0.5ChangeInTheEstimatedUncollectiblePercentageAmount	300000	USD
CY2021	us-gaap	Revenues Revenues	156184000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12676000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	8775000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	644000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	537000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	61000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	44000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	13381000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	9356000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	74000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	111000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	19019000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	14322000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	11386000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	13308000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	7633000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3000000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2400000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1700000	USD
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	6305000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	5721000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3616000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3482000	USD
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	3973000	USD
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	2016000	USD
CY2021Q4	vcel	Accrued Expenses Other Current AccruedExpensesOtherCurrent	151000	USD
CY2020Q4	vcel	Accrued Expenses Other Current AccruedExpensesOtherCurrent	74000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14045000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11293000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	100000	USD
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	7300000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	6300000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	5400000	USD
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	100000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	45720000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	50105000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	73000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	111000	USD
CY2021Q4	vcel	Right Of Use Asset RightOfUseAsset	45793000	USD
CY2020Q4	vcel	Right Of Use Asset RightOfUseAsset	50216000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2950000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4394000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	41000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	41000	USD
CY2021Q4	vcel	Lease Liability Current LeaseLiabilityCurrent	2991000	USD
CY2020Q4	vcel	Lease Liability Current LeaseLiabilityCurrent	4435000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47147000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48789000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	44000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	76000	USD
CY2021Q4	vcel	Lease Liability Noncurrent LeaseLiabilityNoncurrent	47191000	USD
CY2020Q4	vcel	Lease Liability Noncurrent LeaseLiabilityNoncurrent	48865000	USD
CY2021	vcel	Payments For Measurement Of Lease Liability PaymentsForMeasurementOfLeaseLiability	6000000	USD
CY2020	vcel	Payments For Measurement Of Lease Liability PaymentsForMeasurementOfLeaseLiability	5800000	USD
CY2019	vcel	Payments For Measurement Of Lease Liability PaymentsForMeasurementOfLeaseLiability	5000000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2950000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	41000	USD
CY2021Q4	vcel	Lease Liability Payments Due Year One LeaseLiabilityPaymentsDueYearOne	2991000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6634000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	44000	USD
CY2021Q4	vcel	Lease Liability Payments Due Year Two LeaseLiabilityPaymentsDueYearTwo	6678000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6946000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0	USD
CY2021Q4	vcel	Lease Liability Payments Due Year Three LeaseLiabilityPaymentsDueYearThree	6946000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6348000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	USD
CY2021Q4	vcel	Lease Liability Payments Due Year Four LeaseLiabilityPaymentsDueYearFour	6348000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	6530000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	USD
CY2021Q4	vcel	Lease Liability Payments Due Year Five LeaseLiabilityPaymentsDueYearFive	6530000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	36977000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2021Q4	vcel	Lease Liability To Be Paid After Year Five LeaseLiabilityToBePaidAfterYearFive	36977000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	66385000	USD
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	85000	USD
CY2021Q4	vcel	Lease Liability Payments Due LeaseLiabilityPaymentsDue	66470000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	16288000	USD
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	0	USD
CY2021Q4	vcel	Lease Liability Undiscounted Excess Amount LeaseLiabilityUndiscountedExcessAmount	16288000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	50097000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	85000	USD
CY2021Q4	vcel	Lease Liability LeaseLiability	50182000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y7M6D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.050
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.050
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	60909000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	154000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	60755000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	60755000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	66272000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	20000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	-6000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	66286000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	66286000	USD
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5236044	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.34
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	102654000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1683568	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	50.84
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	968261	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.25
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	12126	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	43.48
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	269535	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	26.05
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5669690	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.49
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	113985000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3169562	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	13.07
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	86141000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5359392	shares
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	36000000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	39500000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10500000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	16100000	USD
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44180000	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7471000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	2864000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-9665000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46472000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45221000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2061000	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46472000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47282000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44180000	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.06
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2021Q3	vcel	Sale Of Stock Agreement Expiration Period SaleOfStockAgreementExpirationPeriod	P3Y
CY2021	vcel	Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interest State Taxes IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestStateTaxes	-7471000	USD
CY2020	vcel	Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interest State Taxes IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestStateTaxes	2864000	USD
CY2019	vcel	Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interest State Taxes IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestStateTaxes	-9665000	USD
CY2021	vcel	Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interest State Taxes IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestStateTaxes	-7471000	USD
CY2020	vcel	Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interest State Taxes IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestStateTaxes	2864000	USD
CY2019	vcel	Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interest State Taxes IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestStateTaxes	-9665000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1569000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	601000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2030000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-345000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	200000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-484000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-4311000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	437000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1329000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	47000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	249000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-164000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	413000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	8827000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	0	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	700000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-87000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	132000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-49000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6567000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7388000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4056000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-111000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	180000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11571000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8411000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	11470000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	5692000	USD
CY2021Q4	vcel	Deferred Tax Assets Research And Development Costs DeferredTaxAssetsResearchAndDevelopmentCosts	5059000	USD
CY2020Q4	vcel	Deferred Tax Assets Research And Development Costs DeferredTaxAssetsResearchAndDevelopmentCosts	6411000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2544000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3279000	USD
CY2021Q4	vcel	Deferred Tax Asset Operating Lease Liability DeferredTaxAssetOperatingLeaseLiability	12822000	USD
CY2020Q4	vcel	Deferred Tax Asset Operating Lease Liability DeferredTaxAssetOperatingLeaseLiability	13687000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2833000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	3813000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	10498000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	10085000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	38000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	56810000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	51416000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	43947000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	37379000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	12863000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	14037000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	12266000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	13463000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	597000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	574000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	12863000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14037000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2021Q4	vcel	Operating Loss Carryforwards Limitations On Use Projected Annual Limitation On Use Of Net Operating Losses OperatingLossCarryforwardsLimitationsOnUseProjectedAnnualLimitationOnUseOfNetOperatingLosses	800000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	10500000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6600000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7400000	USD
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1000000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	800000	USD
CY2015Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	600000	USD
CY2015Q4	vcel	Purchase Obligation Renewal Option Term PurchaseObligationRenewalOptionTerm	P5Y
CY2015Q4	vcel	Purchase Obligation Automatic Renewal Term PurchaseObligationAutomaticRenewalTerm	P5Y
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	10135000	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	9254000	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	881000	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2021Q4	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2021Q4	us-gaap	Other Commitment OtherCommitment	8341000	USD
CY2021Q4	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	1445000	USD
CY2021Q4	us-gaap	Other Commitment Due In Second Year OtherCommitmentDueInSecondYear	1513000	USD
CY2021Q4	us-gaap	Other Commitment Due In Third Year OtherCommitmentDueInThirdYear	1432000	USD
CY2021Q4	us-gaap	Other Commitment Due In Fourth Year OtherCommitmentDueInFourthYear	1512000	USD
CY2021Q4	us-gaap	Other Commitment Due In Fifth Year OtherCommitmentDueInFifthYear	1601000	USD
CY2021Q4	us-gaap	Other Commitment Due After Fifth Year OtherCommitmentDueAfterFifthYear	838000	USD
CY2021Q4	us-gaap	Contractual Obligation ContractualObligation	18476000	USD
CY2021Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	10699000	USD
CY2021Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	2394000	USD
CY2021Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	1432000	USD
CY2021Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	1512000	USD
CY2021Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	1601000	USD
CY2021Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	838000	USD

Files In Submission

Name	View Source	Status
0001628280-22-003661-index-headers.html	Edgar Link	pending
0001628280-22-003661-index.html	Edgar Link	pending
0001628280-22-003661.txt	Edgar Link	pending
0001628280-22-003661-xbrl.zip	Edgar Link	pending
ex211subsidiariesofregistr.htm	Edgar Link	pending
ex231consentofregisteredin.htm	Edgar Link	pending
ex311certificationq42021.htm	Edgar Link	pending
ex312certificationq42021.htm	Edgar Link	pending
ex321certificationq42021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vcel-20211231.htm	Edgar Link	pending
vcel-20211231.xsd	Edgar Link	pending
vcel-20211231_cal.xml	Edgar Link	unprocessable
vcel-20211231_def.xml	Edgar Link	unprocessable
vcel-20211231_g1.jpg	Edgar Link	pending
vcel-20211231_htm.xml	Edgar Link	completed
vcel-20211231_lab.xml	Edgar Link	unprocessable
vcel-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2021 Form 10-K Financial Statement

#000162828022003661 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2021 Form 10-K Financial Statement

#000162828022003661 Filed on February 24, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel